Fresenius Kabi
News
May 23, 2022
EuroPN Study: New clinical data on medical nutrition therapy in critically ill patients
read moreApril 30, 2022
Fresenius Kabi SwissBioSim spreads smiles and happiness with a fundraising campaign
read moreApril 29, 2022
Fresenius Kabi Biosimilars team planted trees in Switzerland
read moreMarch 31, 2022
Next generation patient care: Fresenius Kabi buys a majority stake in mAbxience and acquires Ivenix
read moreMarch 30, 2022
Fresenius Kabi receives European Commission approval for its pegfilgrastim biosimilar Stimufend®
read moreOctober 19, 2021
Fresenius Kabi wins Fierce Pharma Award 2021
read moreSeptember 7, 2021
Fresenius Kabi’s tocilizumab biosimilar candidate MSB11456 shows positive results in two clinical trials
read moreFebruary 10, 2021
At the forefront of innovation: Affordable medicine when we need it most
read moreMay 28, 2020
Fresenius Kabi enters marketing agreement for biosimilar product
read moreMay 27, 2020
FDA accepts for review Fresenius Kabi’s first biosimilar regulatory submission for MSB11455, a biosimilar candidate of pegfilgrastim
read more
- June 30, 2022 - July 2, 2022
- |
- Germany, Hamburg
ECOP
European Congress of Oncology Pharmacy
- July 14 - 16, 2022
- |
- USA, InterContinental San Diego
ATOPP
Advanced Topics for Oncology Pharmacy Professionals Summit
- August 9 - 11, 2022
- |
- USA, Bally’s Las Vegas
NPPA
National Pharmacy Purchasing Association
- September 7 - 11, 2022
- |
- Italy, Milan
EADV
European Academy of Dermatology and Venereology
- September 9 - 13, 2022
- |
- France, Paris
ESMO
European Society for Medical Oncology
